ADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results